Jeffrey Berger to Hemorrhage
This is a "connection" page, showing publications Jeffrey Berger has written about Hemorrhage.
Connection Strength
0.427
-
Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. Circ Cardiovasc Interv. 2019 10; 12(10):e008069.
Score: 0.082
-
Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. Am J Cardiovasc Drugs. 2018 Dec; 18(6):457-472.
Score: 0.078
-
Hospital Readmission After Perioperative Acute Myocardial Infarction Associated With Noncardiac Surgery. Circulation. 2018 05 29; 137(22):2332-2339.
Score: 0.074
-
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Curr Med Res Opin. 2017 10; 33(10):1891-1900.
Score: 0.071
-
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26; 385(9):790-802.
Score: 0.023
-
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26; 385(9):777-789.
Score: 0.023
-
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. J Am Coll Cardiol. 2018 10 09; 72(15):1790-1800.
Score: 0.019
-
Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. J Am Coll Cardiol. 2018 10 02; 72(14):1563-1572.
Score: 0.019
-
Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. Eur Heart J Cardiovasc Pharmacother. 2018 10 01; 4(4):220-227.
Score: 0.019
-
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. Clin Ther. 2017 Jul; 39(7):1396-1408.
Score: 0.018